WEBULL
WebtradeDownload

McKesson (MCK) Plans A $2.25b Deal, Is The Stock Fully Valued?

Simply Wall St · 1d ago

McKesson (MCK) has moved back into focus after announcing a planned US$2.25b acquisition of Precision Medicine Group, paired with first quarter results and a larger capital return program.

Recent headlines around the Precision Medicine Group deal and strong first quarter results come as McKesson’s share price has climbed 13.27% over the past 90 days, and its 1-year total shareholder return of 26.75% extends a much larger multiyear gain of roughly 3.4x over five years.

Scan for more healthcare distributors and biopharma service plays showing similar momentum and capital return stories to McKesson by starting with our hand picked 17 high quality undiscovered gems.

McKesson now combines a large healthcare distribution footprint, growing oncology and biopharma services, and a sizable capital return plan. After a sharp share price move, investors may ask whether that strength still comes at a reasonable valuation today.

Most Popular Narrative: 9.1% Undervalued

Against McKesson's last close of $891.68, the most followed narrative points to a fair value of $980.80. This frames the current acquisition news and capital returns inside a story of modest undervaluation rather than stretch pricing.

Increasing complexity of the pharmaceutical supply chain (e.g., biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top-line and margin expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits under that fair value for McKesson? The narrative leans on steady prescription volume, a higher mix of specialty drugs, and slightly richer margins tied to biopharma services and oncology. It also raises questions about how those ingredients could feed into future earnings and the implied multiple on 2029 profits.

Result: Fair Value of $980.80 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, pressure on drug pricing and potential insourcing by large pharmacy benefit managers could chip away at the McKesson thesis if those trends accelerate.

Find out about the key risks to this McKesson narrative.

Next Steps

Mixed signals around McKesson’s upside and risks can feel messy, so move quickly, review the data yourself, and weigh the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond McKesson?

If McKesson has your attention, broaden your watchlist now by lining up other opportunities that match the kind of quality and momentum you care about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.